BMS-564929
Aliases: BMS564929
Last verified: 2026-09-23
The short version
A Bristol-Myers Squibb SARM — potent, selective; development stopped early. Occasionally on the gray market. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Preclinical + early Phase I. Status: discontinued. Not approved; WADA-banned (S1).
Identity & type
- Molecular type
- SARM
- Origin
- A Bristol-Myers Squibb SARM — potent, selective; development stopped early.
Mechanism of action
High-affinity selective AR agonism (20× muscle-vs-prostate selectivity preclinically).
not confirmed in humans
Dosing & routes
Official / clinical context
Development was abandoned; no active regulatory document exists. There are no official indications.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
No human regimens. Almost no contemporary experiences — appears sporadically on the gray market; older reports describe a strong effect with suppression.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Almost no contemporary experiences — appears sporadically on the gray market; older reports describe a strong effect with suppression.
Protocol — official vs community
Official / label
No official protocol exists — this compound has no approved product.
Community (anecdotal)
Structured protocol data for this entry is coming.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. Preclinical + early Phase I.
Preclinical evidence
Preclinical + early Phase I.
Known risks
- Unknown in humans.characterized
- WADA prohibition (S1 anabolic agents)characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.